

Current Status and Future Perspectives on Minimally Invasive Esophagectomy

Hirofumi Kawakubo, M.D., Hiryoza Takeuchi, M.D., Yuko Kitagawa, M.D.

Esophageal cancer has one of the highest malignant potentials of any type of tumor. The 3-field lymph node dissection is the standard procedure in Japan for surgically curable esophageal cancer in the middle or upper thoracic esophagus. Minimally invasive esophagectomy is being increasingly performed in many countries, and several studies report its feasibility and curability; further, the magnifying effect of the thoracoscope is another distinct advantage. However, few studies have reported that minimally invasive esophagectomy is more beneficial than open esophagectomy. A recent meta-analysis revealed that minimally invasive esophagectomy reduces blood loss, respiratory complications, the total morbidity rate, and hospitalization duration. A randomized study reported that the pulmonary infection rate, pain score, intraoperative blood loss, hospitalization duration, and postoperative 6-week quality of life were significantly better with the minimally invasive procedure than with other procedures. In the future, sentinel lymph node mapping might play a significant role by obtaining individualized information to customize the surgical procedure for individual patients' specific needs.

Key words: 1. Esophageal neoplasms
2. Minimally invasive surgical procedures
3. Video-assisted thoracic surgery
4. Sentinel node navigation surgery
5. Lymph node dissection

INTRODUCTION

The global incidence of esophageal cancer has increased in the past decades [1,2], and it has one of the highest malignant potentials of any type of tumor. As per the data of the American Joint Committee on Cancer, the postoperative 5-year survival rate of stage I esophageal cancer is about 90%, and decreases to 45% for stage II, 20% for stage III, and only 10% for stage IV patients [3]. Although the effectiveness of extended lymphadenectomy for esophageal cancer remains to be demonstrated by randomized prospective stud-

ies, better survival was obtained after 3-field lymph node dissection than 2-field lymph node dissection in Japan [4,5]. Three-field lymph node dissection, including dissection of cervical, mediastinal, and abdominal lymph nodes, is the standard procedure employed for surgically curable esophageal cancer located in the middle or upper thoracic esophagus in Japan. The majority of Western surgical groups differ with Japanese groups on their strategy for surgical management of esophageal carcinoma. Many investigators in Europe and the United States have reported that the results of concurrent chemoradiotherapy are comparable to those of surgery [6,7]; how-

Department of Surgery, Keio University School of Medicine

Received: May 26, 2013, Revised: July 8, 2013, Accepted: July 8, 2013

Corresponding author: Yuko Kitagawa, Department of Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582, Tokyo, Japan

(Tel) 81-3-3353-1211 (Fax) 81-3-3355-4707 (E-mail) kitagawa@a3.keio.jp

© The Korean Society for Thoracic and Cardiovascular Surgery. 2013. All right reserved.

© This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Table 1. Contraindication of minimally invasive esophagectomy

| No. | Contraindication |
|-----|--|
| 1 | Extensive pleural adhesions |
| 2 | Tumor infiltrating adjacent structures |
| 3 | Impaired circulatory or pulmonary function prohibiting single-lung ventilation |
| 4 | A concomitant serious medical condition, such as severe diabetes mellitus, chronic renal failure, or liver cirrhosis |
| 5 | Patients refusal to undergo thoracoscopic surgery |
| 6 | Patients who received radiation (controversial) |

ever, most of the surgical procedures in such studies are not as radical as the Japanese standard procedures, and the overall survival rate after surgery is lower than that of the Japanese standard. Nevertheless, some Western surgeons have asserted the importance of radical lymph node dissection [8,9].

Extended lymphadenectomy is extremely invasive and leads to high operative morbidity, particularly because of pulmonary complications [5]. Since the first report of thoracoscopic esophagectomy by Cuschieri et al. [10] in 1992, the adoption of minimally invasive esophagectomy has increased in many countries [11]. Minimally invasive esophagectomy might minimize injury to the chest wall and is believed to reduce surgical invasiveness. Moreover, several reports have indicated its feasibility and curative efficacy [12-15]. Although the incidence of minimally invasive surgery is increasing in Japan, only 20% of esophagectomies performed in 2009 were conducted using a minimally invasive approach [16]. Three-field lymphadenectomy is the standard surgical method employed in Japan; the same degree of lymph node dissection must be performed even for a minimally invasive esophagectomy. Minimally invasive surgery is used less often for esophagectomy, considering the technical challenges of esophagectomy accompanied by extensive lymphadenectomy, which is the Japanese standard surgical method.

Although thoracoscopic esophagectomy has been promoted due to its minimal invasiveness, another distinctive advantage of minimally invasive esophagectomy is the magnifying effect of the thoracoscope, as very small structures can be clearly identified. Thus, the surgery can be performed with more precision, preserving the nerves and vessels.

It has still not been clearly demonstrated whether minimally invasive surgery is associated with lower morbidity and mortality. Furthermore, the oncologic outcomes after mini-

mally invasive surgery are still controversial. Hence, a prospective randomized study of open versus minimally invasive surgery is needed. However, although the incidence of esophageal cancer is increasing, and it is among the 10 most common cancers worldwide, few patients are candidates for potentially curative resection. In addition, a prospective randomized study would be difficult to complete within a reasonable timeframe. Because the technique of minimally invasive surgery is not standardized, even in high volume centers, it is very difficult to set up multi-institutional studies.

INDICATIONS FOR MINIMALLY INVASIVE ESOPHAGECTOMY

Minimally invasive esophagectomy was initially used for T1 and T2 esophageal tumors without neoadjuvant therapy [12,16]. However, the indications for minimally invasive esophagectomy have been expanded to include more advanced cancers. Now, the indications for minimally invasive esophagectomy are almost the same as those for open surgery. The right lung should be deflated during the thoracoscopic procedure to provide a good operative field. Patients must be able to tolerate single-lung ventilation for a sufficient time period. The following are the contraindications for minimally invasive esophagectomy (Table 1): extensive pleural adhesions; a tumor infiltrating adjacent structures; impaired circulatory or pulmonary function prohibiting single-lung ventilation; presence of concomitant serious medical conditions such as severe diabetes mellitus, chronic renal failure, or liver cirrhosis; and patients' refusal to undergo thoracoscopic surgery. Moreover, in our institution, patients who have received radiation in the mediastinum are also contraindicated for minimally invasive esophagectomy because the radiation



Fig. 1. Hybrid position. (A) Prone position. (B) Left semiprone position. (C) Left lateral decubitus position.

might have destroyed the layered structure and have caused tissue adhesions such that the layers cannot be recognized to cut and divide. However, in some institutions, patients are still indicated for minimally invasive surgery after undergoing radiation in the mediastinum [17,18].

APPROACH FOR MINIMALLY INVASIVE ESOPHAGECTOMY

The two approaches for minimally invasive esophagectomy are the prone position and the left lateral decubitus position. Cushieri [19] reported on performing minimally invasive esophagectomy in the prone position for 6 patients in 1994. However, minimally invasive esophagectomy has been most commonly performed in the left lateral decubitus position; nevertheless, since the advantages of this surgery in the prone position have been reported, this position has recently been widely adopted. In the prone position, the mediastinum lies in its usual middle position, and the chest and abdomen are free of compression. During surgery in the prone position, the right lung is partially collapsed by gravity, and the thoracic cavity is insufflated with carbon dioxide up to 8 mmHg. Cuschieri et al. [10] performed the first minimally invasive esophagectomy in the prone position to reduce the incidence of pulmonary infections noted following lateral thoracoscopy. Opening and exposing the mediastinum by gravity and artificial pneumothorax in the prone position allows for optimum visualization of the mediastinum, particularly the middle and lower mediastinum. However, it is easier to explore the surgical field in the upper mediastinum in the left lateral decubitus position, particularly around the left recurrent laryngeal nerve.

The left paratracheal lymph node, which must be dissected, is located anterior to the left recurrent laryngeal nerve. An assistant must skillfully rotate the trachea to expose the surgical field. To achieve constant exposure of the anterior side of the left recurrent laryngeal nerve is very difficult in the prone position; thus, we perform the upper mediastinal procedure in the left lateral decubitus position. The patient is positioned in the left semiprone position during the procedure; this position enables optimal positioning, and the left lateral decubitus position and prone position can be achieved by rotating the surgical table (Fig. 1A, B). Our approach for minimally invasive surgery is a hybrid position: the left lateral decubitus position was selected for the upper mediastinum procedure and the prone position for the middle and lower mediastinum procedure. This hybrid position enables us to immediately convert to from thoracoscopic to open surgery in the event of an emergency, which is an obvious disadvantage of the prone position.

Recently, the advantages of minimally invasive esophagectomy in the prone position have been reported in a large series of nonrandomized historical control studies. Better operative exposure, improved surgeon ergonomics, shorter operative time, less blood loss, and reduced pulmonary infection were observed in the prone position than in the left lateral decubitus position [20-22]. In their historical control study, Noshiro et al. [23] reported the potential benefits of the prone position for thoracoscopic esophagectomy even when accompanied by extensive lymphadenectomy. However, no randomized prospective studies have compared the two approaches, which might be difficult because of the learning curve for both the techniques and because the advantages of each technique

are influenced by the patients and the surgical staff at each institution. Thus, a standard approach cannot be determined.

SURGICAL PROCEDURE

1) Thoracoscopic procedures

The patient is positioned in the left semiprone position. This position is optimal because the left lateral decubitus and prone positions can be achieved by rotating the surgical table. First, the patient is positioned in the left lateral decubitus




Fig. 2. Position for a minithoracotomy and the ports used in our method. (A) Third intercostal space on the midaxillary line; 12-mm trocar. (B) Fifth intercostal space on the posterior axillary line; 5-mm trocar. (C) Seventh intercostal space on the midaxillary line; 12-mm trocar. (D) Seventh intercostal space on the midaxillary line; 12-mm trocar. (E) Tenth intercostal space; 12-mm trocar.

position. Five thoracic trocars and a small incision (4 cm) in the fifth intercostal space are introduced into the right chest (Fig. 2). After the azygos vein arch is divided using the Endo GIA Universal system, the upper thoracic esophagus is mobilized circumferentially, and the paraesophageal and paratracheal lymph nodes along the right and left recurrent laryngeal nerves are dissected (Fig. 3). The thoracic duct is always resected. The right bronchial artery is divided, and the left bronchial artery is always preserved to prevent bronchial ischemia. Subsequently, the patient's bed is rotated to the prone position, and the thoracic cavity is insufflated with 7 mmHg of carbon dioxide to maintain right lung collapse during thoracoscopy. The middle and lower esophagus is mobilized, and the middle and lower paraesophageal, transbronchial, and subcarinal nodes are dissected. The cervical esophagus is divided using the Endo GIA Universal system. The stumps of the esophagus are connected using a string to deliver a gastric conduit to the neck through the posterior mediastinal route.

2) Abdominal and cervical procedures

The patient is placed in the supine position. We perform hand-assisted laparoscopic surgery to dissect the abdominal lymph nodes and create a gastric conduit. A 7.5-cm horizontal minilaparotomy incision is made in the upper right abdomen, and 3 trocars are introduced under laparoscopic guidance. After the left hand of the operator is inserted, the greater omentum is divided 3 to 4 cm from the arcade of the gastroepiploic vessels with the use of a vessel sealing system under an 8-mmHg pneumoperitoneum (Ligasure Blunt chip; Covidien, Mansfield, MA, USA). The left gastroepiploic and short gastric vessels are




Fig. 3. Dissection of paratracheal lymph nodes. (A) Along the right recurrent laryngeal nerve. (B) Along the left recurrent laryngeal nerve.

divided along the splenic hilum, and the gastric fornix is mobilized. The lesser omentum is divided along with preservation of the right gastric vessels. The abdominal esophagus is isolated along the hiatus of the diaphragm, and the thoracic esophagus is pulled into the abdominal space. After the lymph node around the celiac axis is dissected, the left gastric artery and vein are divided. The esophagus and stomach are pulled out from the abdominal incision, creating a gastric conduit.

A collar incision is made above the suprasternal notch. After dissecting the paraesophageal lymph node along the recurrent laryngeal nerves and supraclavicular lymph node, the gastric conduit is pulled out from the cervical incision through the posterior mediastinal route. An esophagogastronomy is performed with a circular stapler.

3) Postoperative management

All of the patients are admitted to the intensive care unit for stabilization and overnight intubation following surgery. Thereafter, patients are detubated the next day and discharged to the general surgical unit on postoperative day 3. Patients are administered epidural analgesia during the first 5 postoperative days and are encouraged to move out of bed after being detubated in order to regain early mobilization from the first day after surgery. Subsequently, patients are discharged when they can consume solid food without aspiration.

CURRENT EVIDENCE FOR MINIMALLY INVASIVE SURGERY

1) Learning curve

Esophagectomy necessitates a certain amount of learning; extensive mediastinal lymph node dissection might require additional experience; and minimally invasive surgery requires much more experience. The benefits of minimally invasive esophagectomy tend to relate to the number of cases experienced. On the basis of patient experience, Leketich et al. [24] concluded that minimally invasive esophagectomy was not beneficial for 8 patients, of uncertain value for 77 patients, and beneficial for 222 patients. Osugi et al. [25] reported that basic skills seem to be acquired during the first 17 cases, and the most remarkable difference was observed between the first 36 cases and the others. According to a re-

port by Ninomiya et al. [26], they safely mastered the basic skills of minimally invasive surgery in a relatively short period of time after only 10 cases of esophageal cancer under the direction of an experienced surgeon and a regular surgical team. Although the surgeon had little experience with esophageal surgery at the beginning, supervision and instruction from another fully trained surgeon allowed the surgeon to safely perform minimally invasive esophagectomy during the induction period. The primary education of the regular surgical team by post-accreditation supervision is essential for safe and rapid to start minimally invasive esophagectomy.

2) Surgical data

A few large comparable studies have reported that minimally invasive esophagectomy is more beneficial than open esophagectomy. Two recent studies have been published: one was a meta-analysis and the other a multicenter, open-label, randomized control trial of minimally invasive surgery versus open surgery.

Nagpal et al. [27] reported a meta-analysis of 12 studies. The studies included a total of 672 patients undergoing minimally invasive surgery and 612 undergoing open esophagectomy. The primary outcomes of their study were 30-day mortality and anastomotic leaks. The secondary outcomes included surgical outcomes, other postoperative outcomes, and oncological outcomes in terms of lymph nodes retrieved. Minimally invasive esophagectomy reduced blood loss, respiratory complications, total morbidity rates, and duration of hospitalization.

Biere et al. [28] from the Netherlands published the TIME trial (traditional invasive vs. minimally invasive esophagectomy) data in the *Lancet*. This was the first report of a multicenter, open-label, randomized control trial to compare minimally invasive esophagectomy and open esophagectomy. They presented evidence of short-term benefits of the minimally invasive technique for patients with resectable cancer of the esophagus or gastroesophageal junction. They randomly assigned 56 patients to the open esophagectomy group and 59 to the minimally invasive esophagectomy group at 5 study centers in 3 countries between June 1, 2009 and March 31, 2011. Sixteen patients (29%) in the open esophagectomy group developed pulmonary infection in the first 2 weeks compared with 5 patients (9%) in the minimally invasive group (relative risk

[RR], 0.30; 95% confidence interval [CI], 0.12 to 0.76; $p=0.005$). Nineteen (34%) of 56 patients in the open esophagectomy group developed a pulmonary infection during hospitalization compared with 7 (12%) of 59 patients in the minimally invasive esophagectomy group (RR, 0.35; 95% CI, 0.16 to 0.78; $p=0.005$). Furthermore, secondary endpoints, including pain score, intraoperative blood loss, duration of hospitalization, and quality of life at 6 weeks after surgery, were significantly better following the minimally invasive procedure than in the open group. However, the pathological parameters, number of lymph nodes retrieved, and postoperative mortality rate did not differ significantly between the two treatment groups. In-hospital mortality rates were low in both the minimally invasive and open groups (2 [3%] of 59 patients vs. 1 [2%] of 56 patients).

3) Oncological results

Few reports are available regarding the long-term outcomes following minimally invasive esophagectomy. In many of the reports, the number of patients and follow-up periods are insufficient [13,16,29,30]. Luketich et al. [14] observed that patient survival at 40 months after surgery was about 70% for stage I patients, but it was as low as 30% and 20% for stage II and III patients, respectively. On the other hand, Smithers et al. [31] analyzed patients who underwent resection using one of three esophagectomy techniques, including open, thoracoscopic-assisted, or a thoracoscopic/laparoscopic approach (total minimally invasive esophagectomy), to assess postoperative variables, adequacy of cancer clearance, and patient survival from a prospective database of all the patients treated for cancer of the esophagus or the esophagogastric junction [31]. The number of patients undergoing each procedure was as follows: open, 114; thoracoscopic-assisted, 309; and total minimally invasive esophagectomy, 23. The nodal harvest for each of the defined regions dissected was not significantly different when the approaches were compared. Further, no difference was observed in the time to recurrence among the 3 groups for patients with invasive cancer, and no difference in patient survival was observed among the groups either.

CONCLUSION

The concepts regarding the sentinel lymph node (SLN), in-

traoperative lymphatic mapping, and sentinel lymphadenectomy appear promising. We have performed radio-guided SLN mapping for cT1aN0 or cT2N0 esophageal cancer to verify the feasibility of SLN mapping. An SLN is defined as the lymph node that is first to receive lymphatic drainage from a tumor site [32]. The SLN is believed to be likely to be the first micrometastasis site along the lymphatic drainage route from the primary lesion. If the SLN is recognized and is negative for metastasis, there might be no metastasis to other lymph nodes. The pathologic status of the SLN is considered to predict the status of all of the regional lymph nodes and might thus avoid unnecessary radical lymph node dissection.

SLN mapping and biopsy were first applied to melanoma and subsequently extended to breast cancer and many other solid tumors [33-36]. These techniques can benefit patients by avoiding various complications that might result from unnecessary radical lymph node dissection in cases wherein the SLN is negative for metastasis. We developed a radio-guided method to detect SLN in esophageal cancer [37] rather than the conventional blue-dye method. One day (within 16 hours) before surgery, a 2.0-mL volume of technetium-99 m tin colloid solution (150 MBq) is injected into the submucosal layer at 4 quadrants around the primary tumor using an endoscopic puncture needle. Preoperative lymphoscintigraphy is usually obtained 3 to 4 hours after injection. The distribution of SLNs in esophageal cancers extends broadly from the cervical to abdominal areas. Takeuchi et al. [38] reported our results of a radio-guided SLN navigation validation study of esophageal cancer; 75 consecutive patients who were diagnosed preoperatively with T1N0M0 or T2N0M0 primary esophageal cancer were enrolled. SLNs were identified in 71 (95%) of 75 patients. The mean number of identified SLNs per case was 4.7; further, 29 (88%) of the 33 patients with LN metastasis revealed positive SLNs, and the diagnostic accuracy on the basis of SLN status was 94%.

Intraoperative SLN (i.e., radio-labeled lymph node) sampling is performed using a handheld gamma probe (GPS Navigator; Covidien, Tokyo, Japan). In addition, gamma probing is feasible for thoracoscopic or laparoscopic sampling of the SLN using a special gamma detector, which is introduced from trocar ports. An SLN located in the cervical

area can be identified by percutaneous gamma probing. All SLNs were sent for an intraoperative pathology examination. SLN mapping was successful during thoracoscopic esophagectomy as well as during a conventional surgical procedure.

In the future, SLN mapping might play a significant role in eliminating the necessity of uniform application of a highly invasive surgery by obtaining individual information to permit adjustments and modifications to the surgical procedure for patients. If SLN is recognized and is negative for metastasis, unnecessary extended lymph node dissection could be avoided. Thus, thoracoscopic surgery with SLN mapping and navigation might become a promising strategy for minimally invasive individualized surgery for early stage esophageal cancer.

CONFLICT OF INTEREST

No potential conflict of interest relevant to this article was reported.

REFERENCES

1. Parkin DM, Pisani P, Ferlay J. *Global cancer statistics*. CA Cancer J Clin 1999;49:33-64.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. *Global cancer statistics*. CA Cancer J Clin 2011;61:69-90.
3. Ando N, Ozawa S, Kitagawa Y, Shinozawa Y, Kitajima M. *Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years*. Ann Surg 2000;232:225-32.
4. Akiyama H, Tsurumaru M, Udagawa H, Kajiyama Y. *Radical lymph node dissection for cancer of the thoracic esophagus*. Ann Surg 1994;220:364-72.
5. Fujita H, Kakegawa T, Yamana H, et al. *Mortality and morbidity rates, postoperative course, quality of life, and prognosis after extended radical lymphadenectomy for esophageal cancer. Comparison of three-field lymphadenectomy with two-field lymphadenectomy*. Ann Surg 1995;222:654-62.
6. Bedenne L, Michel P, Bouche O, et al. *Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102*. J Clin Oncol 2007;25:1160-8.
7. Suntharalingam M. *Definitive chemoradiation in the management of locally advanced esophageal cancer*. Semin Radiat Oncol 2007;17:22-8.
8. Altorki N, Kent M, Ferrara C, Port J. *Three-field lymph node dissection for squamous cell and adenocarcinoma of the esophagus*. Ann Surg 2002;236:177-83.
9. Lerut T, Nafteux P, Moons J, et al. *Three-field lymphadenectomy for carcinoma of the esophagus and gastroesophageal junction in 174 R0 resections: impact on staging, disease-free survival, and outcome: a plea for adaptation of TNM classification in upper-half esophageal carcinoma*. Ann Surg 2004;240:962-72.
10. Cuschieri A, Shimi S, Banting S. *Endoscopic oesophagectomy through a right thoracoscopic approach*. J R Coll Surg Edinb 1992;37:7-11.
11. Lazzarino AI, Nagpal K, Bottle A, Faiz O, Moorthy K, Aylin P. *Open versus minimally invasive esophagectomy: trends of utilization and associated outcomes in England*. Ann Surg 2010;252:292-8.
12. Akaishi T, Kaneda I, Higuchi N, et al. *Thoracoscopic en bloc total esophagectomy with radical mediastinal lymphadenectomy*. J Thorac Cardiovasc Surg 1996;112:1533-40.
13. Osugi H, Takemura M, Higashino M, Takada N, Lee S, Kinoshita H. *A comparison of video-assisted thoracoscopic oesophagectomy and radical lymph node dissection for squamous cell cancer of the oesophagus with open operation*. Br J Surg 2003;90:108-13.
14. Luketich JD, Alvelo-Rivera M, Buenaventura PO, et al. *Minimally invasive esophagectomy: outcomes in 222 patients*. Ann Surg 2003;238:486-94.
15. Committee for Scientific Affairs, Sakata R, Fujii Y, Kuwano H. *Thoracic and cardiovascular surgery in Japan during 2009: annual report by the Japanese Association for Thoracic Surgery*. Gen Thorac Cardiovasc Surg 2011;59:636-67.
16. Kawahara K, Maekawa T, Okabayashi K, et al. *Video-assisted thoracoscopic esophagectomy for esophageal cancer*. Surg Endosc 1999;13:218-23.
17. Shiraishi T, Kawahara K, Shirakusa T, Yamamoto S, Maekawa T. *Risk analysis in resection of thoracic esophageal cancer in the era of endoscopic surgery*. Ann Thorac Surg 2006;81:1083-9.
18. Bizakis C, Kent MS, Luketich JD, et al. *Initial experience with minimally invasive Ivor Lewis esophagectomy*. Ann Thorac Surg 2006;82:402-6.
19. Cuschieri A. *Thoracoscopic subtotal oesophagectomy*. Endosc Surg Allied Technol 1994;2:21-5.
20. Palanivelu C, Prakash A, Senthilkumar R, et al. *Minimally invasive esophagectomy: thoracoscopic mobilization of the esophagus and mediastinal lymphadenectomy in prone position: experience of 130 patients*. J Am Coll Surg 2006;203:7-16.
21. Cadriere GB, Torres R, Dapri G, Capelluto E, Hainaux B, Himpens J. *Thoracoscopic and laparoscopic oesophagectomy improves the quality of extended lymphadenectomy*. Surg Endosc 2006;20:1308-9.
22. Fabian T, Martin J, Katigbak M, McKelvey AA, Federico JA. *Thoracoscopic esophageal mobilization during minimally invasive esophagectomy: a head-to-head comparison of prone versus decubitus positions*. Surg Endosc 2008;22:2485-91.
23. Noshiro H, Iwasaki H, Kobayashi K, et al. *Lymphadenectomy*

- along the left recurrent laryngeal nerve by a minimally invasive esophagectomy in the prone position for thoracic esophageal cancer. *Surg Endosc* 2010;24:2965-73.
24. Luketich JD, Nguyen NT, Weigel T, Ferson P, Keenan R, Schauer P. *Minimally invasive approach to esophagectomy*. *JSL* 1998;2:243-7.
 25. Osugi H, Takemura M, Higashino M, et al. *Learning curve of video-assisted thoracoscopic esophagectomy and extensive lymphadenectomy for squamous cell cancer of the thoracic esophagus and results*. *Surg Endosc* 2003;17:515-9.
 26. Ninomiya I, Osugi H, Fujimura T, et al. *Results of video-assisted thoracoscopic surgery for esophageal cancer during the induction period*. *Gen Thorac Cardiovasc Surg* 2008;56:119-25.
 27. Nagpal K, Ahmed K, Vats A, et al. *Is minimally invasive surgery beneficial in the management of esophageal cancer?: a meta-analysis*. *Surg Endosc* 2010;24:1621-9.
 28. Biere SS, van Berge Henegouwen MI, Maas KW, et al. *Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial*. *Lancet* 2012;379:1887-92.
 29. Law S, Fok M, Chu KM, Wong J. *Thoracoscopic esophagectomy for esophageal cancer*. *Surgery* 1997;122:8-14.
 30. Nguyen NT, Roberts P, Follette DM, Rivers R, Wolfe BM. *Thoracoscopic and laparoscopic esophagectomy for benign and malignant disease: lessons learned from 46 consecutive procedures*. *J Am Coll Surg* 2003;197:902-13.
 31. Smithers BM, Gotley DC, Martin I, Thomas JM. *Comparison of the outcomes between open and minimally invasive esophagectomy*. *Ann Surg* 2007;245:232-40.
 32. Morton DL, Wen DR, Wong JH, et al. *Technical details of intraoperative lymphatic mapping for early stage melanoma*. *Arch Surg* 1992;127:392-9.
 33. Morton DL, Thompson JF, Essner R, et al. *Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial*. *Multicenter Selective Lymphadenectomy Trial Group*. *Ann Surg* 1999;230:453-63.
 34. Krag D, Weaver D, Ashikaga T, et al. *The sentinel node in breast cancer: a multicenter validation study*. *N Engl J Med* 1998;339:941-6.
 35. Bilchik AJ, Saha S, Wiese D, et al. *Molecular staging of early colon cancer on the basis of sentinel node analysis: a multicenter phase II trial*. *J Clin Oncol* 2001;19:1128-36.
 36. Kitagawa Y, Fujii H, Mukai M, et al. *The role of the sentinel lymph node in gastrointestinal cancer*. *Surg Clin North Am* 2000;80:1799-809.
 37. Kitagawa Y, Fujii H, Mukai M, et al. *Intraoperative lymphatic mapping and sentinel lymph node sampling in esophageal and gastric cancer*. *Surg Oncol Clin N Am* 2002;11:293-304.
 38. Takeuchi H, Fujii H, Ando N, et al. *Validation study of radio-guided sentinel lymph node navigation in esophageal cancer*. *Ann Surg* 2009;249:757-63.